Calamos Advisors’s Avita Medical RCEL Stock Holding History

Calamos Advisors’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-210,796	Closed	-$3.08M	–	968
2023 Q3	$3.08M	Buy	210,796 +125,010	+146%	+$2.12M	0.02%	579
2023 Q2	$1.46M	Buy	+85,786	New	+$1.26M	0.01%	677

Other funds holding RCEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Calamos Advisors's RCEL Position: Q4 2023 in Review

Calamos Advisors sold out of Avita Medical (RCEL) in Q4 2023, closing a stake of 210,796 shares — an estimated $3.08M sold.

Calamos Advisors first reported a position in RCEL in Q2 2023 and held it in 2 quarters. The position peaked at $3.08M in Q3 2023. 84 funds tracked by Wall St. Rank hold RCEL as of Q4 2023.

Calamos Advisors reported no remaining Avita Medical position as of Q4 2023 after selling out during the quarter.
Calamos Advisors sold 210,796 Avita Medical shares in Q4 2023, an estimated $3.08M.
Calamos Advisors first reported a position in Avita Medical in Q2 2023 and held it in 2 quarters.
Calamos Advisors's Avita Medical position peaked at $3.08M in Q3 2023.
84 funds tracked by Wall St. Rank held Avita Medical as of Q4 2023.

Based on Calamos Advisors's 13F filing for Q4 2023, filed 31 Jan 2024.